CROI 2017 Program and Information

Program and Agenda

7 IDENTIFYING AND PROFILING VIRUS-SPECIFIC T CELLS USINGMASS CYTOMETRY Evan WilliamNewell, Singapore Immunol Network, Singapore, Singapore 8 QUANTIFYING HIV-1MRNA STRUCTURE AND TRANSLATION EFFICIENCY IN CELLS Silvi Rouskin, Whitehead Institute, Cambridge, MA, USA

WorkshopW4: INTERACTIVE CASE-BASEDWORKSHOP ON HEPATITIS C Room 6 E 2:15 PM - 4:00 PM Target Audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection. Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used. Objectives: At completion of the session, participants will be able to: • Recognize the limitations of current approaches to fibrosis staging • Develop a framework for selection of HCV therapy • Recognize common situations where resistance testing is indicated • Recognize and manage common drug interactions with coinfection • Recognize how treatment approaches differ for persons with cirrhosis Conveners

Preconference Sessions • Monday

Susanna Naggie, Duke Univ, Durham, NC, USA David Wyles, Denver Health, Denver, CO, USA 9 SESSION DESCRIPTION: INTERACTIVE CASE-BASEDWORKSHOP ONHEPATITIS C

APPROACHES TO STAGING AND TREATMENT OF EARLY STAGE HCV John D. Scott, Univ of Washington, Seattle, WA, USA EFFECT OF RAVs ON DAA TREATMENT AND RE-TREATMENT OF PTS WITH CHRONIC HCV INFECTION Alessandra Mangia, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy COMMON DRUG INTERACTIONS WITH HIV/HCV COINFECTION Debika Bhattacharya, Univ of California Los Angeles, Los Angeles, CA, USA CIRRHOSIS ISSUES Sanjay Bhagani, Royal Free Hosp, London, United Kingdom

CROI 2017 31